JCJeppe Romme Christensen

Jeppe Romme Christensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeppe Romme Christensen has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

    by Sahla El Mahdaoui, Luigi Pontieri, Jeppe Romme Christensen, Hiba Alabdalridha, Manuel Demirovic, Luke Karl Harper, Zsolt Illes, Henrik Boye Jensen, Christina Dahl Lindengren, Sepehr Mamoei, et al.


  • Open Access

    Cerebrospinal Fluid sCD27 as a Biomarker of Neuroinflammatory Disease: A Systematic Review and Meta‐Analysis

    by Nadia Damholt Savino, Malene Bredahl Hansen, Amanda Marie Lund Christiansen, Sahla El Mahdaoui, Finn Sellebjerg, Jeppe Romme Christensen

    Neuroinflammatory diseases of the central nervous system (CNS) present considerable diagnostic challenges due to overlapping clinical features and the lack of specific biomarkers capable of reliably detecting CNS inflammation. Soluble CD27 (sCD27) is a marker of adaptive immune activation, released upon CD27–CD70 interaction. sCD27 has emerged as a promising cerebrospinal fluid (CSF) biomarker, but its clinical utility remains unclear. This systematic review and meta‐analysis aimed to clarify the diagnostic value of CSF sCD27 across neuroinflammatory conditions. We systematically searched PubMed, Embase, and Scopus for studies reporting CSF sCD27 levels in neuroinflammatory disorders versus controls, including demyelinating diseases, autoimmune encephalitis, neuroinfectious diseases, and primary CNS lymphoma, following PRISMA 2020 guidelines. Nineteen studies met the inclusion criteria for qualitative synthesis, and ten provided sufficient quantitative data for meta‐analysis, encompassing 685 neuroinflammatory and 751 control participants. Using multivariate and random‐effects models, we found significantly elevated levels of CSF sCD27 in neuroinflammatory diseases compared to controls (standardized mean difference [SMD] = 1.24, 95% CI 0.98–1.51, p < 0.0001), with consistent results in sensitivity and subgroup analysis restricted to multiple sclerosis. Despite between‐study heterogeneity, largely driven by variation in assay methods, reporting units, and study populations, effect sizes remained large and robust. Most studies also reported excellent diagnostic accuracy, with area under the curve (AUC) values above 0.85, supporting the discriminatory potential of CSF sCD27 for neuroinflammatory diseases versus controls. Collectively, these findings strongly support that CSF sCD27 is a robust biomarker of adaptive immune‐mediated neuroinflammation across a spectrum of neuroinflammatory diseases. Future research should focus on assay standardization and consistent reporting practices using well‐characterized prospective cohorts of a broader spectrum of neuroinflammatory disorders to define clinical thresholds and facilitate the integration of CSF sCD27 into diagnostic protocols. This study provides a comprehensive synthesis and substantiates CSF sCD27 as a promising biomarker for detecting adaptive immune‐mediated neuroinflammation in clinical practice. image


  • Open Access

    A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis

    by Camilla Maersk‐Moller, Luigi Pontieri, Morten Leif Munding Stilund, Jeppe Romme Christensen, Lars Kristian Storr, Victoria Hansen, Jakob Schäfer, Arkadiusz Weglewski, Katerina Quinto Romani, Henrik Boye Jensen, et al.

    Background: Ocrelizumab and natalizumab are highly effective disease‐modifying treatments for relapsing–remitting multiple sclerosis (RRMS). Direct comparison of effectiveness is crucial for optimizing treatment decisions and improving patient outcomes. The aim was to compare any difference in effectiveness of ocrelizumab and natalizumab on disease activity and progression in RRMS. Methods: This was a national multicenter comparative effectiveness research study using data from the nationwide population‐based registry of MS cases in Denmark. Patients were included from January 2018 to April 2023 with a history of RRMS treated with ocrelizumab or natalizumab. Inverse probability of treatment weighting based on propensity scores was applied. Main outcomes were the comparison of annualized relapse rate (ARR), time to first progression independent of relapse activity (PIRA), and time to first occurrence of new/enlarging T2 or contrast‐enhancing lesions on cerebral MRI scans. Results: We found no statistically significant differences in the ARR between ocrelizumab‐treated ( n = 542) and natalizumab‐treated ( n = 384) patients (mean [95% CI] ARR of 0.071 [0.057–0.088] and 0.071 [0.054–0.092], respectively) and in the ARR ratio (0.996, 95% CI [0.687–1.444], p = 0.983). Similarly, we did not find differences between the two groups in terms of time to first PIRA (HR, 1.34; 95% CI, 0.88–2.02; p = 0.17) and time to first inflammatory activity in MRI scans (HR, 1.04; 95% CI, 0.74–1.25; p = 0.78). Conclusions: The study could not demonstrate a difference in effectiveness of ocrelizumab and natalizumab treatment in this nationwide population‐based registry study in risk of relapses, disability progression, and MRI activity.


  • Cerebrospinal fluid soluble CD27 is a sensitive biomarker of inflammation in autoimmune encephalitis

    by Stefan Cobanovic, Morten Blaabjerg, Zsolt Illes, Mette Scheller Nissen, Claus Henrik Nielsen, Daniel Kondziella, Sophie Buhelt, Mie Reith Mahler, Finn Sellebjerg, Jeppe Romme Christensen


  • Open Access

    Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial—the MS BOOSTER trial

    by Laurits Taul-Madsen, Lars G Hvid, Finn Sellebjerg, Jeppe Romme Christensen, Rikke Ratzer, Tobias Sejbæk, Kristina Bacher Svendsen, Viktoria Papp, Helene Højsgaard Chow, Jesper Lundbye-Jensen, et al.

    Introduction Multiple sclerosis (MS) causes a broad range of symptoms, with physical function being one of the most disabling consequences according to patients themselves. Exercise effectively improves lower extremity physical function. Nonetheless, it is unknown which exercise modality is most effective and it remains challenging to keep persons with MS adhering to exercise over a longer period. Therefore, the present study aims to investigate how exercise booster sessions (EBS) influence the sustainability of exercise-induced effects on physical function, and furthermore, to investigate which exercise modality (aerobic training or resistance training) is most effective in terms of improving physical function. Materials and methods This study is a multi-arm, parallel-group, open-label multicentre randomised controlled trial investigating the effects of EBS. Participants (n=150) are initially randomised to 12 weeks of either resistance training+usual care, aerobic training+usual care or usual care. After 12 weeks of intervention, participants in the exercise groups will again be randomised to either EBS+usual care or usual care during a 40-week follow-up period. The primary outcome is physical function (composite score based on 6-min walk test and five-time sit to stand), and the secondary outcomes are fatigue, cognition, physical activity, symptoms of depression and quality of life. Ethics and dissemination The study is approved by the Central Denmark Region Committees on Health Research Ethics (1-10-72-237-21) and is registered at the Danish Data Protection Agency (2016-051-000001) and at Clinicaltrials.gov (NCT04913012). All study findings will be published in scientific peer-reviewed journals and presented at scientific conferences. Trial registration number NCT04913012.


  • Open Access

    Association of Cortical Lesions With Regional Glutamate, GABA, N -Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis

    by Mads A. Madsen, Michal Považan, Vanessa Wiggermann, Henrik Lundell, Morten Blinkenberg, Jeppe Romme Christensen, Finn Sellebjerg, Hartwig R. Siebner

    Cortical lesions contribute to disability in multiple sclerosis (MS), but their impact on regional neurotransmitter levels remains to be clarified. We tested the hypothesis that cortical lesions are associated with regional glutamate and gamma-aminobutyric acid (GABA) concentrations within the affected cortical region. In this cross-sectional study, we used structural 7T MRI to segment cortical lesions and 7T proton MR-spectroscopy of the bilateral sensorimotor hand areas to quantify regional GABA, glutamate, N-acetylaspartate, and myoinositol concentrations in patients with MS (inclusion criteria: diagnosis of relapsing-remitting [RR] or secondary progressive MS [SPMS]; age 18-80 years) and age and sex-matched healthy controls. Data were collected at a single center between August 2018 and September 2020. Linear mixed-effects models were used to test for associations between metabolite concentrations and cortical lesion volumes within the same MR-spectroscopy voxel. Forty-seven patients with MS (34 RRMS, 13 SPMS; 45.1 ± 12.5 years; 31 women) and 23 healthy controls (44.4 ± 13 years, 15 women) were studied. In patients, higher regional glutamate and lower regional GABA concentrations were associated with larger cortical lesion volume within the MR-spectroscopy voxel [glutamate: 0.61 (95% CI 0.19-1.03) log(mm3), p = 0.005, GABA: -0.71 (-1.24 to -0.18) log(mm3), p = 0.01]. In addition, lower N-acetylaspartate levels [-0.37 (-0.67 to -0.07) log(mm3), p = 0.016] and higher myoinositol levels [0.48 (0.03-0.93) log(mm3), p = 0.037] were associated with a larger regional cortical lesion volume. Furthermore, glutamate concentrations were reduced in patients with SPMS compared with healthy participants [-0.75 (-1.3 to -0.19) mM, p = 0.005] and patients with RRMS [-0.55 (-1.07 to -0.02) mM, p = 0.04]. N-acetylaspartate levels were lower in both patients with RRMS [-0.81 (-1.39 to -0.24) mM, p = 0.003] and SPMS [-1.31 (-2.07 to -0.54) mM, p < 0.001] when compared with healthy controls. Creatine-normalized N-acetylaspartate levels were associated with performance in the 9-hole peg test of the contralateral hand [-0.004 (-0.007 to -0.002) log(s), p = 0.002], and reduced mean creatine-normalized glutamate was associated with increased Expanded Disability Status Scale (R = -0.39, p = 0.02). Cortical lesions are associated with local increases in glutamate and a reduction in GABA concentration within the lesional or perilesional tissue. Further studies are needed to investigate the causal relationship between cortical lesions and changes in neurotransmitter concentrations.


  • Open Access

    CD11c+ B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy

    by Sahla El Mahdaoui, Marie Mathilde Hansen, Marina Rode von Essen, Victoria Hyslop Hvalkof, Rikke Holm Hansen, Mie Reith Mahler, Poul Jennum, Finn Sellebjerg, Jeppe Romme Christensen

    Objectives: B cells are important in the pathogenesis of multiple sclerosis. It is yet unknown which subsets may be involved, but atypical B cells have been proposed as mediators of autoimmunity. In this study, we investigated differences in B‐cell subsets between controls and patients with untreated and anti‐CD20‐treated multiple sclerosis.Methods: We recruited 155 participants for an exploratory cohort comprising peripheral blood and cerebrospinal fluid, and a validation cohort comprising peripheral blood. Flow cytometry was used to characterize B‐cell phenotypes and effector functions of CD11c+ atypical B cells.Results: There were no differences in circulating B cells between controls and untreated multiple sclerosis. As expected, anti‐CD20‐treated patients had a markedly lower B‐cell count. Of B cells remaining after treatment, we observed higher proportions of CD11c+ B cells and plasmablasts. CD11c+ B cells were expanded in cerebrospinal fluid compared to peripheral blood in controls and untreated multiple sclerosis. Surprisingly, the proportion of CD11c+ cerebrospinal fluid B cells was higher in controls and after anti‐CD20 therapy than in untreated multiple sclerosis. Apart from the presence of plasmablasts, the cerebrospinal fluid B‐cell composition after anti‐CD20 therapy resembled that of controls. CD11c+ B cells demonstrated a high potential for both proinflammatory and regulatory cytokine production.Interpretation: The study demonstrates that CD11c+ B cells and plasmablasts are less efficiently depleted by anti‐CD20 therapy, and that CD11c+ B cells comprise a phenotypically and functionally distinct, albeit heterogenous, B‐cell subset with the capacity of exerting both proinflammatory and regulatory functions.


  • Open Access

    Linking cortical lesions to metabolic changes in multiple sclerosis using 7T proton MR spectroscopy

    by Mads Alexander Just Madsen, Michal Považan, Vanessa Wiggermann, Henrik Lundell, Morten Blinkenberg, Jeppe Romme Christensen, Finn Sellebjerg, Hartwig Roman Siebner

    Importance: Cortical lesions contribute to disability in multiple sclerosis (MS) but their impact on regional neurotransmitter levels remains to be clarified. Objective: To test the hypothesis that cortical lesions in MS alter the regional concentrations of the main excitatory and inhibitory neurotransmitters, glutamate and gamma-aminobutyric acid (GABA), in the affected cortex. Design: Prospective, cross-sectional, observational proton MR-spectroscopy ( 1 H-MRS) and structural MRI study at 7T. Setting: Data were collected at a single center between August 2018 and September 2020. Participants: A volunteer sample of 57 MS patients and 38 healthy participants were screened for participation in the study. 50 MS patients and 28 healthy participants were included. In the final cohort, three patients and five healthy participants were excluded due to drop out (n=6) or insufficient data-quality (n=2). Exposures: Two-voxel 7T 1 H-MRS covering the right and left sensorimotor hand areas (SM1-HAND) and high-resolution structural brain 7T MRI. Main outcome: Regional concentrations of glutamate and GABA in SM1-HAND and their relation to cortical lesion volume within the MRS voxel. Results: Data from 34 relapsing remitting (RR) and 13 secondary progressive (SP)MS patients (mean +/− standard deviation, 45.1 +/− 12.5 years, 31 female) along with 23 age- and sex-matched healthy participants (44.4 +/− 13 years, 15 female) entered data-analyses. Patient data were pooled to assess the relationship between cortical lesion volume and neurotransmitter levels. Larger cortical lesion volume within SM1-HAND was associated with higher regional glutamate (0.61 +/− 0.21 log(mm 3 ), P=0.005) and lower regional GABA (−0.71 +/− 0.27 log(mm 3 ), P=0.01) concentration. Between-group comparison showed that glutamate concentration within the SM1-voxel was reduced in SPMS patients compared to healthy participants (−0.75 +/− 0.24 mM, P=0.004) and RRMS patients (−0.55 +/− 0.22 mM, P=0.04), while regional GABA levels did not differ among groups. Conclusion: Our results link cortical lesion load in SM1-HAND with regional glutamate and GABA levels in patients with RRMS and SPMS, showing a shift in balance between regional excitatory and inhibitory neurotransmitters towards increased excitation with increasing cortical lesion volume. Between-group comparisons provide preliminary evidence that a progressive disease course may be associated with a decrease in cortical glutamate levels. Key points: Question: How do cortical lesions change the regional metabolic profile in multiple sclerosis? Findings: This observational cross-sectional study employed voxel-based proton MR-spectroscopy ( 1 H-MRS) of the primary sensorimotor hand areas (SM1-HAND) at ultra-high field (7T) to show that cortical lesions alter regional concentrations of glutamate and gamma-aminobutyric acid (GABA) in patients with multiple sclerosis. We found that higher regional glutamate concentrations were associated with larger regional cortical lesion volume, whereas higher GABA concentrations were associated with lower regional cortical lesion volume. Meaning: These findings suggest that cortical lesions shift the regional excitation-inhibition balance towards excitation.

  • Acute posterior multifocal placoid pigment epitheliopathy resembling multiple sclerosis

    by Sahla El Mahdaoui, Asher Lou Isenberg, Klaus Hansen, Annika Reynberg Langkilde, Steffen Hamann, Jeppe Romme Christensen

    A 23-year-old man presented with right eye blurred vision; he was diagnosed with acute posterior multifocal placoid pigment epitheliopathy (APMPPE), and his symptoms resolved with prednisolone. Two months later, he developed a right arm weakness that resolved after 3 weeks. MR scan of brain identified changes suggesting multiple sclerosis, with four hyperintense FLAIR lesions; there was contrast enhancement of two lesions and no diffusion restriction. Cerebrospinal fluid showed mononuclear pleocytosis. We eventually diagnosed these as APMPPE-associated CNS lesions. APMPPE is a rare inflammatory chorioretinopathy that rarely can resemble multiple sclerosis clinically and radiologically.

  • Open Access

    Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7 T MRI study

    by Mads A J Madsen, Vanessa Wiggermann, Marta F M Marques, Henrik Lundell, Stefano Cerri, Oula Puonti, Morten Blinkenberg, Jeppe Romme Christensen, Finn Sellebjerg, Hartwig R Siebner

    Cortical lesions constitute a key manifestation of multiple sclerosis and contribute to clinical disability and cognitive impairment. Yet it is unknown whether local cortical lesions and cortical lesion subtypes contribute to domain-specific impairments attributable to the function of the lesioned cortex. In this cross-sectional study, we assessed how cortical lesions in the primary sensorimotor hand area relate to corticomotor physiology and sensorimotor function of the contralateral hand. Fifty relapse-free patients with relapsing–remitting or secondary–progressive multiple sclerosis and 28 healthy age- and sex-matched participants underwent whole-brain 7 T MRI to map cortical lesions. Brain scans were also used to estimate normalized brain volume, pericentral cortical thickness, white matter lesion fraction of the corticospinal tract, infratentorial lesion volume and the cross-sectional area of the upper cervical spinal cord. We tested sensorimotor hand function and calculated a motor and sensory composite score for each hand. In 37 patients and 20 healthy controls, we measured maximal motor-evoked potential amplitude, resting motor threshold and corticomotor conduction time with transcranial magnetic stimulation and the N20 latency from somatosensory-evoked potentials. Patients showed at least one cortical lesion in the primary sensorimotor hand area in 47 of 100 hemispheres. The presence of a lesion was associated with worse contralateral sensory (P = 0.014) and motor (P = 0.009) composite scores. Transcranial magnetic stimulation of a lesion-positive primary sensorimotor hand area revealed a decreased maximal motor-evoked potential amplitude (P < 0.001) and delayed corticomotor conduction (P = 0.002) relative to a lesion-negative primary sensorimotor hand area. Stepwise mixed linear regressions showed that the presence of a primary sensorimotor hand area lesion, higher white-matter lesion fraction of the corticospinal tract, reduced spinal cord cross-sectional area and higher infratentorial lesion volume were associated with reduced contralateral motor hand function. Cortical lesions in the primary sensorimotor hand area, spinal cord cross-sectional area and normalized brain volume were also associated with smaller maximal motor-evoked potential amplitude and longer corticomotor conduction times. The effect of cortical lesions on sensory function was no longer significant when controlling for MRI-based covariates. Lastly, we found that intracortical and subpial lesions had the largest effect on reduced motor hand function, intracortical lesions on reduced motor-evoked potential amplitude and leucocortical lesions on delayed corticomotor conduction. Together, this comprehensive multilevel assessment of sensorimotor brain damage shows that the presence of a cortical lesion in the primary sensorimotor hand area is associated with impaired corticomotor function of the hand, after accounting for damage at the subcortical level. The results also provide preliminary evidence that cortical lesion types may affect the various facets of corticomotor function differentially.